Research progress on gut microbiota in patients with gastric cancer, esophageal cancer, and small intestine cancer

Chen, Changchang; Chen, Linjie; Lin, Lijun; Jin, Dazhi; Du, Yaoqiang; Lyu, Jianxin

doi:10.1007/s00253-021-11358-z

Cited by 23 publications

(22 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The exact mechanisms of gut microbes on clinical response are not well understood. Gut microflora could regulate cancer development through Inflammatory reaction, Immune reaction, specific protein activation, carcinogenic metabolite production (34). It's important that gut microbes have broader effects on immune cells, such as, dendritic cells (DCs), natural killer (NK) cell, and the subset of T cell (CD4 + T cell, CD8 + T cell or Th17 cells) in tumor microenvironment.…”

Section: Discussionmentioning

confidence: 99%

Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy

Xu¹,

Qi²,

Jiang³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background:The gut microbiome is associated with the response to immunotherapy in a variety of advanced cancers. However, the influence of the gut microbiome on locally advanced esophageal squamous cell carcinoma (ESCC) during programmed cell death protein 1 (PD-1) antibody immunotherapy plus chemotherapy is not clearly demonstrated. To explore the crosstalk between the gut microbiome and clinical response in locally advanced thoracic ESCC during neoadjuvant camrelizumab and chemotherapy Methods: Patients who were diagnosed with locally advanced thoracic ESCC and had not received treatment were enrolled. The treatment regimen was two cycles of camrelizumab combined with carboplatin and albumin paclitaxel before surgery. The research endpoints were pathological complete response (pCR) and major pathological response (MPR). Fecal samples were collected at three time points: before neoadjuvant therapy, after two cycles of neoadjuvant therapy, and after surgery. We performed 16S ribosomal ribonucleic acid (rRNA) V3-V4 sequencing of the gene amplicons of fecal samples, as well as bacterial diversity and differential abundance analyses.Results: A total of 46 patients were recruited, and 44, 42, and 35 fecal samples were collected at the three time points, respectively. Statistically significant differences were observed in the amplicon sequence variant (ASV)-level alpha diversity indices, including Chao1, Shannon, and Good's coverage, between the three time points. The non-pCR-enriched gut microbiota included Proteobacteria, Dialister, Aeromonadales,

show abstract

Section: Discussionmentioning

confidence: 99%

Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy

Xu¹,

Qi²,

Jiang³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…Overall, the above risk factors for esophageal cancer are well described in the literature in contrast to the gut microbiota which, may also play a role in carcinogenesis according to recent published studies ( Chen C et al., 2021 ; Zhou et al., 2021 ). Therefore, in this review, we briefly discussed the role of the gut microbiota in esophageal carcinogenesis and its alterations in esophageal cancer patients.…”

Section: Introductionmentioning

confidence: 94%

Esophageal cancer and bacterial part of gut microbiota – A multidisciplinary point of view

Muszyński

Kudra

Sobocki

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

There is an urgent need to search for new screening methods that allow early detection of esophageal cancer and thus achieve better clinical outcomes. Nowadays, it is known that the esophagus is not a sterile part of the gastrointestinal tract. It is colonized with various microorganisms therefore a “healthy” esophageal microbiome exists. The dysbiotic changes of esophageal microbiome can lead to the development of esophageal diseases including esophageal cancer. There is a strong consensus in the literature that the intestinal microbiome may be involved in esophageal carcinogenesis. Recently, emphasis has also been placed on the relationship between the oral microbiome and the occurrence of esophageal cancer. According to recent studies, some of the bacteria present in the oral cavity, such as Tannerella forsythia, Streptococcus anginosus, Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, and Fusobacterium nucleatum may contribute to the development of this cancer. Moreover, the oral microbiome of patients with esophageal cancer differs significantly from that of healthy individuals. This opens new insights into the search for a microbiome-associated marker for early identification of patients at high risk for developing this cancer.

show abstract

“…was found to be enriched to approx. 20% in the latter [32]. Presently, it is thought that unfavourable gut microbiota may promote cancer development by multiple mechanisms, e.g., immune response changes and carcinogenic metabolite production [33].…”

Section: Targeting the Gut Microbiome In Oncologymentioning

confidence: 99%

Microbiota in Health and Disease—Potential Clinical Applications

et al. 2021

View full text Add to dashboard Cite

Within the last two decades tremendous efforts in biomedicine have been undertaken to understand the interplay of commensal bacteria living in and on our human body with our own human physiology. It became clear that (1) a high diversity especially of the microbial communities in the gut are important to preserve health and that (2) certain bacteria via nutrition-microbe-host metabolic axes are beneficially affecting various functions of the host, including metabolic control, energy balance and immune function. While a large set of evidence indicate a special role for small chain fatty acids (SCFA) in that context, recently also metabolites of amino acids (e.g., tryptophan and arginine) moved into scientific attention. Of interest, microbiome alterations are not only important in nutrition associated diseases like obesity and diabetes, but also in many chronic inflammatory, oncological and neurological abnormalities. From a clinician’s point of view, it should be mentioned, that the microbiome is not only interesting to develop novel therapies, but also as a modifiable factor to improve efficiency of modern pharmaceutics, e.g., immune-therapeutics in oncology. However, so far, most data rely on animal experiments or human association studies, whereas controlled clinical intervention studies are spare. Hence, the translation of the knowledge of the last decades into clinical routine will be the challenge of microbiome based biomedical research for the next years. This review aims to provide examples for future clinical applications in various entities and to suggest bacterial species and/or microbial effector molecules as potential targets for intervention studies.

show abstract

Research progress on gut microbiota in patients with gastric cancer, esophageal cancer, and small intestine cancer

Cited by 23 publications

References 96 publications

Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy

Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy

Esophageal cancer and bacterial part of gut microbiota – A multidisciplinary point of view

Microbiota in Health and Disease—Potential Clinical Applications

Contact Info

Product

Resources

About